Bulletin du Cancer
MENUTargeting ErbB receptors in breast cancer Volume 94, supplement 6, Suppl. FMC numéro 7 : Thérapeutiques ciblées : malades sélectionnés
Figures
Centre Georges-François Leclerc, rue du Professeur Marion, 21079 Dijon, Centre René Gauducheau, Saint-Herblain
- Key words: breast cancers, ErbB2, HER2, EGFR, trastuzumab, lapatinib
- DOI : 10.1684/bdc.2007.0432
- Page(s) : 147-70
- Published in: 2007
Because of the involvement of the receptors of the ErbB family in breast oncogenesis, numerous approaches aimed at targeting these receptors have been developed. A monoclonal anibody directed against the ErbB2 (HER2) receptor, trastuzumab (Herceptin ®), has shown a high activity in palliative, neo-adjuvant and, more recently, in adjuvant setting, and has been considered as bringing a “therapeutic revolution” in breast oncology. Other antibodies, directed against ErbB2 or EGFR, are being evaluated, especially lapatinib, which should be marketed in the next future. Combinations between targeted therapies and cytotoxic chemotherapy will certainly allow to take the greatest benefits from these new treatment approaches.